Supriya Lifescience Limited (BOM:543434)
India · Delayed Price · Currency is INR 890.20
-24.85 (-2.72%)
At close: Oct 7, 2026
Supriya Lifescience Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 6, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 71,669 | 45,223 | 59,086 | 26,797 | 15,352 | 39,702 | |
Market Cap Growth | 21.80% | -23.46% | 120.50% | 74.55% | -61.33% | - |
Enterprise Value | 70,935 | 44,243 | 58,298 | 25,696 | 13,821 | 39,457 |
Last Close Price | 915.05 | 564.43 | 731.57 | 330.42 | 189.55 | 489.09 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 6, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 37.14 | 21.63 | 31.44 | 22.50 | 17.09 | 26.15 |
PS Ratio | 8.44 | 5.46 | 8.48 | 4.70 | 3.33 | 7.49 |
PB Ratio | 6.15 | 3.78 | 5.93 | 3.29 | 2.19 | 6.45 |
P/TBV Ratio | 6.16 | 3.78 | 5.94 | 3.29 | 2.20 | 6.46 |
P/FCF Ratio | 219.69 | 134.86 | 2570.09 | - | - | - |
P/OCF Ratio | 39.66 | 24.34 | 35.88 | 23.65 | 24.14 | 81.36 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 6, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 8.36 | 5.34 | 8.37 | 4.51 | 3.00 | 7.44 |
EV/EBITDA Ratio | 25.19 | 15.04 | 22.42 | 14.67 | 10.79 | 18.47 |
EV/EBIT Ratio | 28.17 | 16.60 | 24.24 | 16.04 | 11.80 | 19.31 |
EV/FCF Ratio | 217.50 | 131.94 | 2535.82 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 6, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 | 0.05 |
Debt / EBITDA Ratio | 0.02 | 0.02 | 0.02 | 0.03 | 0.17 | 0.13 |
Debt / FCF Ratio | - | 0.16 | 2.34 | - | - | - |
Net Debt / Equity Ratio | -0.06 | -0.06 | -0.07 | -0.08 | -0.19 | -0.32 |
Net Debt / EBITDA Ratio | -0.25 | -0.25 | -0.28 | -0.40 | -1.05 | -0.92 |
Net Debt / FCF Ratio | - | -2.19 | -32.09 | 2.15 | 3.05 | 17.79 |
Asset Turnover | - | 0.67 | 0.68 | 0.66 | 0.59 | 0.90 |
Inventory Turnover | - | 2.08 | 2.30 | 2.31 | 1.89 | 2.47 |
Quick Ratio | - | 2.47 | 2.46 | 2.48 | 2.60 | 3.47 |
Current Ratio | - | 4.40 | 5.07 | 5.16 | 4.85 | 4.99 |
Return on Equity (ROE) | - | 19.06% | 20.74% | 15.73% | 13.66% | 34.34% |
Return on Assets (ROA) | - | 13.46% | 14.74% | 11.50% | 9.42% | 21.64% |
Return on Invested Capital (ROIC) | 17.03% | 19.82% | 21.80% | 17.58% | 17.36% | 44.51% |
Return on Capital Employed (ROCE) | - | 21.60% | 23.30% | 19.00% | 16.20% | 32.20% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 6, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 2.69% | 4.62% | 3.18% | 4.45% | 5.85% | 3.82% |
FCF Yield | 0.46% | 0.74% | 0.04% | -1.21% | -2.89% | -0.28% |
Dividend Yield | 0.11% | 0.18% | 0.14% | 0.24% | 0.32% | 0.12% |
Payout Ratio | - | 3.85% | 3.43% | 4.05% | 5.37% | 2.89% |
Buyback Yield / Dilution | 0.03% | - | - | - | - | -9.97% |
Total Shareholder Return | 0.13% | 0.18% | 0.14% | 0.24% | 0.32% | -9.85% |